Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027 Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA loss Guides to end FY2026 with cash and cash equivalents of $70 million Company to host investment community conference call on March 5, 2026WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today reported financial results...

The annual accounts of Kaldalón hf. for the year 2025 were approved by the company’s board of directors on 4 March 2026. Key highlights of the 2025 Annual Accounts:Target of a ISK 100 billion property portfolio within reach based on existing agreements Operating profit and rental income increased by 24% year-on-year Profit before tax amounted to ISK 3,525 million Cash generated from operations amounted to ISK 2,711 million The Board of Directors proposes a dividend payment of ISK 1,000 million  2025  2024Operating revenues 5,598  4,508Revenue Weighted occupancy rate of delivered properties 97,6%  97,1%Operating profit before fair value adjustments 4,387  3,548Operation net profit margin   78,4%  78,7%Gains on fair value adjustements    3,168  3,991Profit before tax 3,525  4,311Return on equity 12,5%  13,3%Cash...

ATHENS, Greece, March 04, 2026 (GLOBE NEWSWIRE) — Performance Shipping Inc. (NASDAQ: PSHG) (“we” or the “Company”), a global shipping company specializing in the ownership of tanker vessels, today reported net income of $7.6 million for the fourth quarter of 2025, compared to a net income of $9.7 million for the same period in 2024. Earnings per share, basic and diluted, for the fourth quarter of 2025 were $0.57 and $0.19, respectively. Revenue was $26.2 million ($24.6 million net of voyage expenses) for the fourth quarter of 2025, compared to $21.7 million ($19.8 million net of voyage expenses) for the same period in 2024. This increase was mainly attributable to the increase in ownership days following the delivery of the newbuilding vessels P. Massport and P. Tokyo in July and September 2025, respectively. Fleetwide, the average...

YANTAI, China, March 04, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (Nasdaq: DXST) (“Decent“ or the ”Company“), an established wastewater treatment services provider in China, today announced its financial results for the fiscal year ended October 31, 2025. Fiscal Year 2025 Financial HighlightsTotal revenue for fiscal year 2025 increased by 12.2% to US$12.9 million, from US$11.5 million for fiscal year 2024. Revenue from wastewater treatment service increased by 68.7% to US$4.2 million from US$2.5 million in the prior fiscal year, primarily due to the completion of a wastewater treatment project during fiscal year 2025. Gross profit for fiscal year 2025 grew by 5.42% to $3.4 million, even though the gross profit margin declined to 26.1% from 27.8% in the prior year.Mr. Dingxin Sun, Chairman of the Company, commented: “Fiscal...

Conference Call and Webcast Today at 8:30 a.m. ETEnrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027. OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission. OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026. First regional licensing agreement for OCU400 in 2025 initiates strategic partnership strategy ahead of commercialization Rounded out executive leadership team with top talent in business...

Exceeds Top End of Fiscal 2026 Revenue Outlook and Reports Record Q4 ResultsOperational Excellence Drives Record Free Cash FlowCompletes Strategic Acquisition of Power Solutions Accelerating Entry into High-Growth Data Center MarketFiscal 2027 Outlook Reflects Continued Organic Contract Revenue Growth and Adjusted EBITDA Margin Expansion Fourth Quarter Highlights(All metrics compared to the fourth quarter of fiscal 2025)Contract revenues of $1.458 billion(*) increased 34.4%, or 16.6% organically Net income of $16.3 million, or $0.55 per common share diluted Adjusted Net Income of $60.5 million(*), or $2.03(*) per common share diluted Adjusted EBITDA of $162.4 million(*), or 11.1% of contract revenues Operating cash flow of $419.0 million(*) Total backlog of $9.542 billion(*) Completed acquisition of Power Solutions, LLC on December 23,...

TORONTO, March 04, 2026 (GLOBE NEWSWIRE) — George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 13 weeks ended December 31, 2025(2). GWL’s 2025 Annual Report includes the Company’s audited annual consolidated financial statements and Management’s Discussion and Analysis (“MD&A”) for the fiscal year ended December 31, 2025. The 2025 Annual Report has been filed on SEDAR+ and is available at www.sedarplus.ca and in the Investor Centre section of the Company’s website at www.weston.ca. As a result of the Company’s reporting calendar, the fourth quarter and full year 2025 include an extra week of operations (“the 13th week” or “the 53rd week”)(1) compared to the fourth quarter and full year 2024. “2025 marked another strong year for George Weston as Loblaw gained...

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Announced expansion of heme program with FDA clearance of TSC-102-A01 and TSC-102-A03 targeting CD45, in patients with HLA types A*01:01 and A*03:01 Cash and cash equivalents continue to fund operations into the second half of 2027 WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) —  TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three...

        – Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments. “Following a year of exceptional execution across our pivotal DURAVYU...

CALGARY, Alberta, March 04, 2026 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three- and twelve-month periods ended December 31, 2025, as well as the results of its independent reserves assessment as at December 31, 2025. Additionally, the Company declares its Q1 2026 regular dividend of C$0.385 per share and provides an operational update. All amounts herein are in United States dollars (“USD”) unless otherwise stated. Key HighlightsGenerated annual funds flow provided by operations (“FFO”)(1) of $455 million and free funds flow(2) of $145 million in 2025. Increased both PDP and 1P reserves per share by 4% and 2P reserves per share by 8%, compared to 2024(3). Strong PDP, 1P, and 2P reserves replacement at 106%, 106%,...